RT Journal Article SR Electronic T1 Metastatic risk stratification of leiomyosarcoma patients using transcription- and replication-associated chromosomal instability mechanisms JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.29.21250218 DO 10.1101/2021.01.29.21250218 A1 Benhaddou, Ataaillah A1 Gaston, Laetitia A1 Pérot, Gaëlle A1 Desplat, Nelly A1 Leroy, Laura A1 Guellec, Sophie Le A1 Haddou, Mohamed Ben A1 Rochaix, Philippe A1 Valentin, Thibaud A1 Ferron, Gwenaël A1 Chevreau, Christine A1 Bui, Binh A1 Stoeckle, Eberhard A1 Cesne, Axel Le A1 Piperno-Neumann, Sophie A1 Colin, Françoise A1 Firmin, Nelly A1 De Pinieux, Gonzague A1 Coindre, Jean-Michel A1 Blay, Jean-Yves A1 Chibon, Frédéric YR 2021 UL http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250218.abstract AB Leiomyosarcoma (LMS) is an aggressive smooth muscle cancer with few therapeutic options. LMSs show a high level of genomic instability (GI) and the mechanisms underlying their oncogenic processes are poorly understood. While the level of GI influences treatment efficacy and resistance, an accurate measure of it is lacking. Current measures of GI are based on counts of specific structural variation (SV) and mutational signatures. Here, we present a holistic approach to measuring GI based on the quantification of the steady-state equilibrium between DNA damage and repair as assessed by the residual breakpoints (BP) remaining after repair, irrespective of SV type. We use the notion of Hscore, a BP “hotspotness” magnitude scale, to measure the propensity of genomic structural or functional DNA elements to break more than expected by chance. We then derived new measures of transcription- and replication-associated GI that we call iTRAC (Transcription-Associated Chromosomal instability index (iTRAC) and iRACIN (Replication-Associated Chromosomal INstability index). We show that iTRAC and iRACIN are predictive of metastatic relapse in LMS and that they may be combined to form a new classifier called MAGIC (Mixed transcription-and replication-Associated Genomic Instability Classifier). MAGIC outperforms the gold standards FNCLCC and CINSARC in stratifying metastatic risk in LMS. Furthermore, iTRAC stratifies chemotherapeutic response in LMS. We finally show that this approach is applicable to other cancers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the French Sarcoma Group for tumor banks and associated clinical annotations and to Jean-Baptiste Courrèges. The following French cancer centers also participated in this study: Centre Paul Papin (Angers), Centre Oscar Lambert (Lille), Institut Paoli Calmettes (Marseille), CHU La Timone (Marseille), CHU Bordeaux and hospital Ambroise Paré (Paris). This work was supported by grant from the Instituts Thematiques Multiorganismes (ITMO) Cancer (INSERM and INCa) and the Claudius Regaud Institute. The authors would like to thank the Centre Nacional d'Anàlisi Genòmica (CNAG, Barcelona, Spain) for WG sequencing services. We thank GENOTOUL for bioinformatics facilities and computer farm.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human blood and tissue samples were collected and analyzed with approved protocols in accordance with the ethical requirements and regulations of the French National Cancer Institute review board. The ethics of this study was validated by French committee for protection of persons (CPP). Informed consent was obtained from all subjects. Peripheral blood was obtained from cancer patients diagnosed with sarcoma at various stages and treated within the French Sarcoma Group.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript is available as supplemental tables or described in material and methods section